A5045644761- Research on Leishmaniasis Studies
- Trypanosoma species research and implications
- Toxin Mechanisms and Immunotoxins
- Immunotherapy and Immune Responses
- Viral gastroenteritis research and epidemiology
- Hepatitis B Virus Studies
- vaccines and immunoinformatics approaches
- Virus-based gene therapy research
- Brucella: diagnosis, epidemiology, treatment
- Parasites and Host Interactions
- Antimicrobial Peptides and Activities
- Insect and Pesticide Research
- Transgenic Plants and Applications
- Escherichia coli research studies
- RNA Interference and Gene Delivery
- Blood Coagulation and Thrombosis Mechanisms
- Cervical Cancer and HPV Research
- Monoclonal and Polyclonal Antibodies Research
- Heat shock proteins research
- Hepatitis C virus research
- Toxoplasma gondii Research Studies
- Viral Infections and Vectors
- Herpesvirus Infections and Treatments
- Hepatitis Viruses Studies and Epidemiology
- Immune Response and Inflammation
Pasteur Institute of Iran
2016-2025
Wilfrid Laurier University
2006
Université Laval
2006
Institut Pasteur
2003
Abstract In populations exposed to Leishmania braziliensis, certain subjects develop skin ulcers, whereas others are naturally protected against cutaneous leishmaniasis. We have evaluated which cytokines most crucial in the development of lesions. found that active lesions occur with polarized Th2 or mixed Th1/Th2 responses, both associated elevated IL-10 production. was strongly (p = 0.004, odd ratio (OR) 6.8, confidence interval 1.9–25) lesions, excluding IFN-γ, IL-12, TNF, IL-13, and IL-4...
Host protection against several intracellular pathogens requires the induction of CD8(+) T cell responses. cells are potent effector that can produce high amounts pro-inflammatory cytokines and kill infected target efficiently. However, a protective role for during Leishmania infections is still controversial largely depends on infection model. In this review, we discuss various types infections, following vaccination, as potential immunotherapeutic targets.
Novel vaccination approaches are needed to prevent leishmaniasis. Live attenuated vaccines the gold standard for protection against intracellular pathogens such as Leishmania and there have been new developments in this field. The nonpathogenic humans lizard protozoan parasite, (L) tarentolae, has used effectively a vaccine platform visceral leishmaniasis experimental animal models. Correspondingly, pre-exposure sand fly saliva or immunization with salivary protein shown protect mice...
Visceral leishmaniasis (VL) is a vector-borne disease affecting humans and domestic animals that constitutes serious public health problem in many countries. Although antigens have been examined so far as protein- or DNA-based vaccines, none of them conferred complete long-term protection. The use the lizard non-pathogenic to Leishmania (L.) tarentolae species live vaccine vector deliver specific recent approach needs be explored further. In this study, we evaluated effectiveness vaccination...
Leishmaniasis caused by protozoan parasites of the genus Leishmania. Intracellular infections treatment such as leishmaniasis is frequently hampered limited access drugs to infected cells. Moreover, most current are confined some toxic compounds, and there increasing incidences development drug resistance. Hence, production a new antileishmanial compound crucial. Paromomycin sulphate (PM) promising drug. One strategy improve effectiveness use appropriate delivery systems. Solid lipid...
Abstract Parasites are responsible for the most neglected tropical diseases, affecting over a billion people worldwide (WHO, 2015) and accounting billions of cases year several millions deaths. Research on extracellular vesicles (EVs) has increased in recent years demonstrated that EVs shed by pathogenic parasites interact with host cells playing an important role parasite's survival, such as facilitation infection, immunomodulation, parasite adaptation to environment transfer drug...
Background As a potent CD8+ T cell activator, peptide vaccine has found its way in development against intracellular infections and cancer, but not leishmaniasis. The first step toward is epitope mapping of different proteins according to the most frequent HLA types population. Methods Findings Six Leishmania (L.) major-related candidate antigens (CPB,CPC,LmsTI-1,TSA,LeIF LPG-3) were screened for potential activating 9-mer epitopes presented by HLA-A*0201 (the HLA-A allele). Online software...
Proliferation of Leishmania (L.) parasites depends on polyamine availability, which can be generated by the L-arginine catabolism and enzymatic activity arginase (ARG) mammalian hosts. In present study, we characterized compared (arg) genes from pathogenic L. major tropica non-pathogenic tarentolae. We quantified level ARG in promastigotes macrophages infected with tarentolae amastigotes. The ARG's amino acid sequences demonstrated virtually 98.6% 88% identities reference Friedlin ARG....
A Leishmania protein vaccine elicited immune responses and mediated strong cross-species protection.
Currently, there is no topical treatment available for any form of cutaneous leishmaniasis (CL) in most the endemic areas. The aim current study was to develop a nano-liposomal Amphotericin B (AmB) CL. Liposomes containing 0.1, 0.2 and 0.4% AmB (Lip-AmB) were formulated characterized size, entrapment efficiency, long term stability, skin penetration properties using Franz diffusion cells. diameters around 100 nm with change during more than 20 months' storage either at 4 °C or room...